Floatz logo

Cetrelimab

Small Cell Carcinoma

Rahul Aggarwalmonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

18 Active assets in the Small Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Hycamtin
National Cancer Institute (NCI)
Phase 2BB
ETOPOSIDE
SystImmune Inc.
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
EpicentRx, Inc.
Phase 2BB
Lurbinectedin
SystImmune Inc.
Phase 3BB
Vinorelbine
EpicentRx, Inc.
Phase 2BB

View all 31 →

Same molecule, other indications

Cetrelimab is also rated in:

prostate cancerDormant
B
Indicative ·
60 / 100
View asset →
castration-resistant prostate carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →
metastatic prostate carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →